Windtree Therapeutics Stock Current Ratio

WINT Stock

USD 0.31 0.01 3.13%

Windtree Therapeutics fundamentals help investors to digest information that contributes to Windtree Therapeutics' financial success or failures. It also enables traders to predict the movement of Windtree Stock. The fundamental analysis module provides a way to measure Windtree Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Windtree Therapeutics stock.

		Last Reported	Projected for Next Year
	Current Ratio	1.35	1.28

Current Ratio is likely to drop to 1.28 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Windtree Therapeutics Company Current Ratio Analysis

Windtree Therapeutics' Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

Current Ratio

Current Asset

Current Liabilities

More About Current Ratio | All Equity Analysis

Current Windtree Therapeutics Current Ratio

2.47 X

Most of Windtree Therapeutics' fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Windtree Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Windtree Current Ratio Driver Correlations

Understanding the fundamental principles of building solid financial models for Windtree Therapeutics is extremely important. It helps to project a fair market value of Windtree Stock properly, considering its historical fundamentals such as Current Ratio. Since Windtree Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Windtree Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Windtree Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Current Deferred Revenue	Long Term Debt	Treasury Stock	Property Plant Equipment	Net Receivables	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Short Long Term Debt	Deferred Long Term Liab	Net Invested Capital	Net Working Capital	Good Will	Capital Stock	Intangible Assets
Total Assets		0.96	-0.46	-0.36	0.21	0.73	0.45	-0.26	-0.32	-0.17	0.0	-0.34	-0.06	0.29	0.33	0.18	0.49	-0.47	0.57	0.84	0.69	0.18	0.11	0.09
Total Stockholder Equity	0.96		-0.59	-0.15	0.07	0.52	0.5	-0.44	-0.15	-0.15	-0.16	-0.18	-0.04	0.08	0.41	0.02	0.34	-0.43	0.49	0.77	0.63	0.26	0.18	0.13
Net Debt	-0.46	-0.59		-0.23	0.1	-0.03	-0.91	0.51	0.11	-0.12	-0.1	0.17	-0.04	0.12	-0.65	-0.13	0.24	-0.07	0.21	0.02	0.03	-0.41	-0.35	-0.27
Retained Earnings	-0.36	-0.15	-0.23		-0.13	-0.64	0.14	-0.11	0.76	-0.08	-0.02	0.71	-0.51	-0.9	0.26	-0.05	-0.86	0.61	-0.71	-0.47	-0.6	0.53	0.55	0.62
Accounts Payable	0.21	0.07	0.1	-0.13		0.55	0.13	0.44	-0.34	0.21	0.58	-0.37	-0.57	0.28	0.16	0.6	0.04	0.41	-0.14	0.14	-0.12	0.37	0.43	0.45
Total Liab	0.73	0.52	-0.03	-0.64	0.55		0.22	0.31	-0.59	-0.11	0.46	-0.6	-0.12	0.61	0.03	0.57	0.66	-0.29	0.49	0.67	0.52	0.12	0.06	0.04
Total Current Assets	0.45	0.5	-0.91	0.14	0.13	0.22		-0.3	-0.22	0.04	0.46	-0.26	-0.12	0.04	0.73	0.45	-0.19	0.17	-0.28	-0.1	-0.17	0.38	0.37	0.33
Short Term Debt	-0.26	-0.44	0.51	-0.11	0.44	0.31	-0.3		-0.14	0.04	0.52	-0.16	-0.37	0.15	-0.35	0.46	0.01	0.37	-0.21	-0.11	-0.21	0.21	0.2	0.23
Common Stock	-0.32	-0.15	0.11	0.76	-0.34	-0.59	-0.22	-0.14		-0.57	-0.26	0.99	-0.32	-0.94	-0.01	-0.28	-0.43	0.23	-0.25	-0.21	-0.23	0.14	0.15	0.16
Current Deferred Revenue	-0.17	-0.15	-0.12	-0.08	0.21	-0.11	0.04	0.04	-0.57		-0.07	-0.59	0.14	0.37	0.03	-0.1	-0.27	0.3	-0.27	-0.22	-0.24	0.15	0.16	0.17
Long Term Debt	0.0	-0.16	-0.1	-0.02	0.58	0.46	0.46	0.52	-0.26	-0.07		-0.3	-0.47	0.22	0.23	0.92	-0.13	0.44	-0.45	-0.28	-0.43	0.35	0.39	0.42
Treasury Stock	-0.34	-0.18	0.17	0.71	-0.37	-0.6	-0.26	-0.16	0.99	-0.59	-0.3		-0.27	-0.9	-0.03	-0.32	-0.37	0.19	-0.2	-0.21	-0.21	0.04	0.07	0.08
Property Plant Equipment	-0.06	-0.04	-0.04	-0.51	-0.57	-0.12	-0.12	-0.37	-0.32	0.14	-0.47	-0.27		0.35	-0.11	-0.58	0.44	-0.51	0.5	0.04	0.37	-0.57	-0.69	-0.85
Net Receivables	0.29	0.08	0.12	-0.9	0.28	0.61	0.04	0.15	-0.94	0.37	0.22	-0.9	0.35		-0.11	0.24	0.6	-0.41	0.42	0.27	0.32	-0.38	-0.34	-0.35
Net Tangible Assets	0.33	0.41	-0.65	0.26	0.16	0.03	0.73	-0.35	-0.01	0.03	0.23	-0.03	-0.11	-0.11		0.14	-0.26	0.15	-0.17	-0.07	-0.25	0.16	0.21	0.2
Long Term Debt Total	0.18	0.02	-0.13	-0.05	0.6	0.57	0.45	0.46	-0.28	-0.1	0.92	-0.32	-0.58	0.24	0.14		-0.04	0.33	-0.34	-0.08	-0.24	0.39	0.51	0.47
Capital Surpluse	0.49	0.34	0.24	-0.86	0.04	0.66	-0.19	0.01	-0.43	-0.27	-0.13	-0.37	0.44	0.6	-0.26	-0.04		-0.72	0.9	0.68	0.78	-0.49	-0.54	-0.64
Short Long Term Debt	-0.47	-0.43	-0.07	0.61	0.41	-0.29	0.17	0.37	0.23	0.3	0.44	0.19	-0.51	-0.41	0.15	0.33	-0.72		-0.81	-0.63	-0.75	0.49	0.52	0.58
Deferred Long Term Liab	0.57	0.49	0.21	-0.71	-0.14	0.49	-0.28	-0.21	-0.25	-0.27	-0.45	-0.2	0.5	0.42	-0.17	-0.34	0.9	-0.81		0.81	0.89	-0.51	-0.56	-0.66
Net Invested Capital	0.84	0.77	0.02	-0.47	0.14	0.67	-0.1	-0.11	-0.21	-0.22	-0.28	-0.21	0.04	0.27	-0.07	-0.08	0.68	-0.63	0.81		0.9	0.01	-0.06	-0.13
Net Working Capital	0.69	0.63	0.03	-0.6	-0.12	0.52	-0.17	-0.21	-0.23	-0.24	-0.43	-0.21	0.37	0.32	-0.25	-0.24	0.78	-0.75	0.89	0.9		-0.17	-0.25	-0.45
Good Will	0.18	0.26	-0.41	0.53	0.37	0.12	0.38	0.21	0.14	0.15	0.35	0.04	-0.57	-0.38	0.16	0.39	-0.49	0.49	-0.51	0.01	-0.17		0.9	0.82
Capital Stock	0.11	0.18	-0.35	0.55	0.43	0.06	0.37	0.2	0.15	0.16	0.39	0.07	-0.69	-0.34	0.21	0.51	-0.54	0.52	-0.56	-0.06	-0.25	0.9		0.8
Intangible Assets	0.09	0.13	-0.27	0.62	0.45	0.04	0.33	0.23	0.16	0.17	0.42	0.08	-0.85	-0.35	0.2	0.47	-0.64	0.58	-0.66	-0.13	-0.45	0.82	0.8

Click cells to compare fundamentals

Windtree Current Ratio Historical Pattern

Today, most investors in Windtree Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Windtree Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current ratio growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Windtree Therapeutics current ratio as a starting point in their analysis.

Windtree Therapeutics Current Ratio

Timeline

Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).

Competition

Predict Windtree Therapeutics

Current Ratio Over Time

Windtree Price To Sales Ratio

Price To Sales Ratio

633.15

At this time, Windtree Therapeutics' Price To Sales Ratio is comparatively stable compared to the past year.

In accordance with the recently published financial statements, Windtree Therapeutics has a Current Ratio of 2.47 times. This is 15.12% lower than that of the Biotechnology sector and 64.71% lower than that of the Health Care industry. The current ratio for all United States stocks is 14.35% lower than that of the firm.

Windtree Current Ratio Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Windtree Therapeutics' direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Windtree Therapeutics could also be used in its relative valuation, which is a method of valuing Windtree Therapeutics by comparing valuation metrics of similar companies.

Windtree Therapeutics is currently under evaluation in current ratio category among its peers.

Windtree Fundamentals

	Return On Equity	-1.51
	Return On Asset	-0.45
	Current Valuation	2.5 M
	Shares Outstanding	8.75 M
	Shares Owned By Insiders	0.27 %
	Shares Owned By Institutions	0.59 %
	Number Of Shares Shorted	496.99 K
	Price To Earning	(0.05) X
	Price To Book	0.63 X
	Price To Sales	660.53 X
	Gross Profit	(17.79 M)
	EBITDA	(20.16 M)
	Net Income	(20.29 M)
	Cash And Equivalents	11.38 M
	Cash Per Share	0.37 X
	Total Debt	16.83 M
	Debt To Equity	0.95 %
	Current Ratio	2.47 X
	Book Value Per Share	5.90 X
	Cash Flow From Operations	(13.44 M)
	Short Ratio	0.06 X
	Earnings Per Share	(19.03) X
	Target Price	7.0
	Beta	0.64
	Market Capitalization	4.92 M
	Total Asset	32.41 M
	Retained Earnings	(844.82 M)
	Working Capital	1.38 M
	Current Asset	40.79 M
	Current Liabilities	11.07 M
	Net Asset	32.41 M

About Windtree Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Windtree Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Windtree Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Windtree Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Windtree Stock Analysis

When running Windtree Therapeutics' price analysis, check to measure Windtree Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Windtree Therapeutics is operating at the current time. Most of Windtree Therapeutics' value examination focuses on studying past and present price action to predict the probability of Windtree Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Windtree Therapeutics' price. Additionally, you may evaluate how the addition of Windtree Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC